## Abstract Number: [44]

Abstract Title: Spanish Society of Neurology Consensus and recommendations on multiple sclerosis treatment Abstract Category: Therapy - 42 - Others Preferred Presentation Type: Oral or poster presentation

Celia Oreja-Guevara<sup>\*1, 2</sup>, Sergio Martinez Yelamos<sup>3</sup>, Sara Eichau<sup>4</sup>, Miguel Angel Llaneza Gonzalez<sup>5</sup>, Jesus Martin Martinez<sup>6</sup>, Joaquin Peña Martinez<sup>7</sup>, Virginia Meca<sup>8</sup>, Ana María Alonso Torres<sup>9</sup>, Ester Moral Torres<sup>10</sup>, Jordi Rio<sup>11</sup>, Carmen Calles<sup>12</sup>, Adrian Ares Luque<sup>13</sup>, Lluís Ramió-Torrentà<sup>14, 15</sup>, María Eugenia Marzo Sola<sup>16</sup>, José Maria Prieto Gonzáles<sup>17</sup>, Marisa Luisa Martinez Gines<sup>18</sup>, Rafael Arroyo<sup>19</sup>, Maria Angeles Otano Martinez<sup>20</sup>, Luis Brieva Ruiz<sup>21</sup>, Montserrat Gomez<sup>22</sup>, Alfredo Rodriguez-Antigüedad<sup>23</sup>, Victoria Galan Sanchez-Seco<sup>24</sup>, Lucienne Costa-Frossard<sup>25</sup>, Miguel Angel Hernandez<sup>26</sup>, Lamberto Landete<sup>27</sup>, Montserrat Gonzalez Platas<sup>28</sup>, Jose Meca Lallana<sup>29, 30</sup>

<sup>1</sup>Hospital Clínico San Carlos, IdISSC, Department of Neurology, Madrid, Spain, <sup>2</sup>Facultad de Medicina, Universidad Complutense de Madrid (UCM), Department of Medicine, Madrid, Spain, <sup>3</sup>Multiple Sclerosis Unit "EMxarxa". Department of Neurology. H.U. de Bellvitge. IDIBELL. Department of Clinical Science. Universitat de Barcelona, Barcelona, Spain, <sup>4</sup>Hospital Universitario Virgen Macarena, Department of Neurology, Sevilla, Spain, <sup>5</sup>Complejo Hospitalario Universitario de Ferrol, Department of Neurology, Ferrol, Spain, <sup>6</sup>Hospital Universitario Miguel Servet, Department of Neurology, Zaragoza, Spain, <sup>7</sup>Hospital Universitario San Agustín, Department of Neurology, Avilés, Spain, <sup>8</sup>Hospital Universitario La Princesa, Department of Neurology, Madrid, Spain, <sup>9</sup>Hospital Regional Universitario de Málaga, Department of Neurology, Málaga, Spain, <sup>10</sup>Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain, <sup>11</sup>CemCat-Vall d'Hebrón, Department of Neurology, Barcelona, Spain, <sup>12</sup>Hospital Universitari Son Espases, Department of Neurology, Palma de Mallorca, Spain, <sup>13</sup>Complejo Asistencial Universitario de León, Department of Neurology, León, Spain, <sup>14</sup>Hospital Universitario Dr. Josep Trueta and Hospital Santa Caterina, IDIBGI, Multiple Sclerosis and Neuroimmunology Unit, Girona, Spain, <sup>15</sup>Universidad de Girona, Department of Medical Science, Girona, Spain, <sup>16</sup>Hospital San Pedro, Department of Neurology, Logroño, Spain, <sup>17</sup>Complejo Hospitalario Universitario de Santiago, Department of Neurology, Santiago de Compostela, Spain, <sup>18</sup>Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Department of Neurology, Madrid, Spain, <sup>19</sup>Hospital Universitario Quiron Salud Madrid, Department of Neurology, Madrid, Spain, <sup>20</sup>Complejo Hospitalario de Navarra, Department of Neurology, Navarra, Spain, <sup>21</sup>Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Lleida, Spain, <sup>22</sup>Hospital Universitario de Cáceres, Department of Neurology, Cáceres, Spain, <sup>23</sup>Hospital Universitario Cruces, Department of Neurology, Barakaldo, Spain, <sup>24</sup>Hospital Universitario de Toledo, Department of Neurology, Toledo, Spain, <sup>25</sup>Ramón y Cajal University Hospital, Multiple Sclerosis Unit, Madrid, Spain, <sup>26</sup>Hospital Nuestra Señora de Candelaria, Department of Neurology, Santa Cruz de Tenerife, Spain, <sup>27</sup>Hospital Universitario Dr Peset, Department of Neurology, Valencia, Spain, <sup>28</sup>Hospital Universitario de Canarias, Department of Neurology, La Laguna, Spain, <sup>29</sup>Clinic Neuroimmunology Unit and Multiple Sclerosis CSUR, Department of Neurology, Murcia, Spain, <sup>30</sup>Hospital Clínico Universitario Virgen de la Arrixaca (IMIB-Arrixaca)/Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, Universidad Católica San Antonio (UCAM), Murcia, Spain

## Introduction:

Given the complexity of multiple sclerosis (MS) and the substantial changes in its therapeutic approach, there is a growing need to create consensus, guidelines and recommendations to help

# MSMilan2O23 9th Joint ECTRIMS-ACTRIMS Meeting 11–13 October 2023 | Milan, Italy

neurologists to make decisions in their routine clinical practice. Several countries are developing their own consensus considering the particularities each country. Given the heterogenicity of the regionalized Spanish healthcare system, there was a need of a national consensus involving experts representing different Autonomous Communities.

#### **Objectives/Aims:**

The aim of this study was to offer a set of recommendations relating to the comprehensive management of MS patients in clinical practice in Spain. **Methods:** 

The items elaborated by the scientific committee were grouped into nine dimensions related to the management of the pathology, including early diagnosis, early start of DMT, escalation versus early start of high-efficacy DMT, face-to-face and remote follow-up, suboptimal response detection, patient perspective, biomarkers and pregnancy, as well as vaccination. Using the Delphi methodology, 21 neurologists (expert panel) provided the results for generating the final recommendations.

### **Results:**

The panel recommends that after MS diagnosis, the choice of initial treatment should not be based on "treatment lines", but mainly on the presence or absence of poor prognostic factors for the appearance of relapses or disability progression. Furthermore, the panel emphasizes the importance of using validated tools for assessing the patient experience. While several potential biomarkers have been proposed, the panel considered that further validation and standardization is required before it is feasible and useful enough to use them in routine clinical practice.

#### Conclusion:

This consensus document provides a set of recommendations for the comprehensive management of MS patients in Spanish clinical practice. The recommendations are expected to optimize patient care and improve their quality of life.

**Disclosures:** The authors declare fees for lectures, consultations, assistance to congresses, advisory meetings, personal compensation, teaching or research from: Actelion, Alexion, Almirall, Aventis, Bayer, Bial, Biogen Idec, BMS, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genzyme, GW Pharma, Janssen, Merck, Novartis, Roche, Sandoz, Sanofi, Teva, UCB Pharma and Viatris.

**Travel / Abstract Grant Application and Young Scientific Investigators' Session:** I will not apply for Travel Grant or Young Scientific Investigators' Session

Which one would you like to apply to:

Date of Birth: